Literature DB >> 7931664

Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis.

P J Lewis1, A Salama.   

Abstract

Whole-body PET scanning was performed using 18F-fluorodeoxyglucose (FDG) in two patients with hilar lymphadenopathy in whom the clinical differential diagnosis was between sarcoidosis and lymphoma. Both patients were later proven to have sarcoidosis. Uptake of 18FDG was seen in both intra- and extrathoracic lesions as well as in associated erythema nodosum. One patient underwent a repeat scan after steroid therapy where a marked decrease in hilar uptake was seen. Fluorine-18-fluorodeoxyglucose uptake is observed in lymph nodes with sarcoid involvement. Further investigation is necessary to assess if quantitative differences exist between sarcoid and malignant lymphadenopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931664

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC).

Authors:  D Le Guludec; R Lautamäki; J Knuuti; J J Bax; F M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-26       Impact factor: 9.236

3.  The detection of recurrent sarcoidosis by FDG-PET in a lung transplant recipient.

Authors:  C Kiatboonsri; S C Resnick; K M Chan; R G Barbers; C C Marboe; A Khonsary; S M Santiago; O P Sharma
Journal:  West J Med       Date:  1998-02

4.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.

Authors:  M Sasaki; Y Ichiya; Y Kuwabara; Y Akashi; T Yoshida; T Fukumura; S Murayama; T Ishida; K Sugio; K Masuda
Journal:  Eur J Nucl Med       Date:  1996-07

5.  FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future.

Authors:  Abass Alavi; Thomas J Werner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

6.  Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET.

Authors:  Songji Zhao; Yuji Kuge; Min Yi; Yan Zhao; Toshiyuki Hatano; Keiichi Magota; Ken-ichi Nishijima; Masashi Kohanawa; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

7.  Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors.

Authors:  Songji Zhao; Yuji Kuge; Masashi Kohanawa; Toshiyuki Takahashi; Hidekazu Kawashima; Takashi Temma; Toshiki Takei; Yan Zhao; Koh-ichi Seki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

Review 8.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

10.  F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection.

Authors:  Koen S Simons; Peter Pickkers; Chantal P Bleeker-Rovers; Wim J G Oyen; Johannes G van der Hoeven
Journal:  Intensive Care Med       Date:  2009-10-22       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.